vactosertib   Click here for help

GtoPdb Ligand ID: 8107

Synonyms: EW-7197 | EW7197 | NOV-1301 | TEW-7197
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The discovery of vactosertib (EW-7197) is reported in [1] where it is compound 12b. EW-7197 acts as in inhibitor of transforming growth factor beta receptor 1B (TGFβR1; ALK5) and activin A receptor type IB (ACVR1B; ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 5
Topological polar surface area 83.79
Molecular weight 399.16
XLogP 3.56
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1cccc(n1)c1[nH]c(nc1c1ccc2n(c1)ncn2)CNc1ccccc1F
Isomeric SMILES Cc1cccc(n1)c1[nH]c(nc1c1ccc2n(c1)ncn2)CNc1ccccc1F
InChI InChI=1S/C22H18FN7/c1-14-5-4-8-18(27-14)22-21(15-9-10-20-25-13-26-30(20)12-15)28-19(29-22)11-24-17-7-3-2-6-16(17)23/h2-10,12-13,24H,11H2,1H3,(H,28,29)
InChI Key FJCDSQATIJKQKA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
EW-7197 (research coded TEW-7197) is being evaluated in Phase 1 clinical trials: NCT02160106 (a first in human dose escalation study in patients with solid tumours) and NCT03143985 (in combination with pomalidomide in patients with relapsed or relapsed/refractory multiple myeloma).